SCHEMBL10165579

SCHEMBL10165579

COC(=O)NS(=O)(=O)c1ccc(NC(=O)C(C)Oc2ccc(Cl)cc2C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
KDM4E B2RXH2 3/20 0.62
MAPT P10636 3/20 0.62
HPGD P15428 2/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
ALDH1A1 P00352 2/20 0.54
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.54
TRPM4 Q8TD43 1/20 0.53
LMNA P02545 3/20 0.51
POLB P06746 3/20 0.51
ALOX12 P18054 1/20 0.51
RECQL P46063 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TSHR P16473 2/20 0.50
MAPK1 P28482 2/20 0.50
HTR2A P28223 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165501 1.00 MEN1 (0.62) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL10165447 1.00 MEN1 (0.62) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL15113261 0.81 MEN1 (0.75) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL10165480 0.81 L3MBTL1 (0.56) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL10165527 0.81 L3MBTL1 (0.56) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL10165583 0.81 L3MBTL1 (0.56) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL134430 0.80 MEN1 (0.58) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4897413 0.80 MEN1 (0.58) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL8754455 0.80 TRPM4 (0.68) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL21225837 0.77 KMT2A (0.54) MEN1KMT2AKDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883766-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-11 US disclosed
US-8883766-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-11 US disclosed
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE CACNA1G, CACNA1C, CACNA1B MEN1 3385/4885KMT2A 2348/4885KDM4E 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.